Cargando…

Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry

BACKGROUND: The monoclonal antibody natalizumab (NTZ) is a highly effective treatment for patients with multiple sclerosis (MS). However, this drug is associated with increased risk of developing Progressive Multifocal Leukoencephalopathy (PML), an opportunistic infection of central nervous system (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prosperini, Luca, de Rossi, Nicola, Scarpazza, Cristina, Moiola, Lucia, Cosottini, Mirco, Gerevini, Simonetta, Capra, Ruggero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5172579/ https://www.ncbi.nlm.nih.gov/pubmed/27997580 http://dx.doi.org/10.1371/journal.pone.0168376

Ejemplares similares

Lack of specific T- and B-cell clonal expansions in multiple sclerosis patients with progressive multifocal leukoencephalopathy
por: Bertoli, Diego, et al.
Publicado: (2019)

Natalizumab: Progressive multifocal leukoencephalopathy: case report
Publicado: (2021)

Changes in Brain Volumes Are Relevant during Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: Lessons from a Case Report
por: De Masi, Roberto, et al.
Publicado: (2022)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis
por: Herold, Tina Rike, et al.
Publicado: (2012)

Natalizumab-associated Progressive Multifocal Leukoencephalopathy in Patients with Multiple Sclerosis: A Mini Review
por: Fayyaz, Muniba, et al.
Publicado: (2018)

Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
por: Lo Buono, Viviana, et al.
Publicado: (2022)

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy
por: Metz, Imke, et al.
Publicado: (2011)

Risk of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patient Treated With Natalizumab: A Systematic Review
por: Vivekanandan, Govinathan, et al.
Publicado: (2021)

Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy
por: Dong-Si, Tuan, et al.
Publicado: (2015)

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
por: Toorop, Alyssa A., et al.
Publicado: (2020)

Early Magnetic Resonance Detection of Natalizumab-Related Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Sclerosis
por: Manenti, Guglielmo, et al.
Publicado: (2013)

Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
por: Sinnecker, Tim, et al.
Publicado: (2016)

Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
por: Perkins, Molly R., et al.
Publicado: (2012)

Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk
por: Hartung, Hans-Peter, et al.
Publicado: (2021)

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab
por: Diotti, Roberta Antonia, et al.
Publicado: (2016)

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
por: McGuigan, C, et al.
Publicado: (2016)

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients
por: Dahlhaus, Stefanie, et al.
Publicado: (2013)

Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience
por: Perncezky, Julian, et al.
Publicado: (2022)

Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings
por: Mattioli, Flavia, et al.
Publicado: (2015)

Presymptomatic Diagnosis with MRI and Adequate Treatment Ameliorate the Outcome after Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
por: Lindå, Hans, et al.
Publicado: (2013)

Insight into Metabolic (1)H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions
por: Schneider, Ruth, et al.
Publicado: (2017)

Multidisciplinary Rehabilitation is Efficacious and Induces Neural Plasticity in Multiple Sclerosis even when Complicated by Progressive Multifocal Leukoencephalopathy
por: Groppo, Elisabetta, et al.
Publicado: (2017)

Pre-Existing T- and B-Cell Defects in One Progressive Multifocal Leukoencephalopathy Patient
por: Sottini, Alessandra, et al.
Publicado: (2012)

Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML
por: Alleg, Manel, et al.
Publicado: (2020)

Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
por: Zanghì, Aurora, et al.
Publicado: (2021)

Adoptive Transfer of JC Virus‐Specific T Lymphocytes for the Treatment of Progressive Multifocal Leukoencephalopathy
por: Berzero, Giulia, et al.
Publicado: (2021)

Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
por: Plavina, Tatiana, et al.
Publicado: (2014)

Progressive Multifocal Leukoencephalopathy
por: Adang, Laura, et al.
Publicado: (2015)

Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS): “a case report from Ireland with review of literature, clinical pitfalls and future direction”
por: Mansoor, Salman, et al.
Publicado: (2021)

Progressive multifocal leukoencephalopathy in Finland: a cross-sectional registry study
por: Sipilä, Jussi O. T., et al.
Publicado: (2019)

Metabolic profiles by (1)H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)
por: Schneider, Ruth, et al.
Publicado: (2017)

Treatment of progressive multifocal leukoencephalopathy
por: Castle, Daniel, et al.
Publicado: (2019)

Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question
por: De Mercanti, Stefania Federica, et al.
Publicado: (2020)

Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study
por: Pontillo, Giuseppe, et al.
Publicado: (2017)

Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing
por: Rempe, Torge, et al.
Publicado: (2020)

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis
por: Prosperini, Luca, et al.
Publicado: (2019)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies
por: Hatchwell, Eli, et al.
Publicado: (2022)

Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
por: Lyons, Jennifer, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_666io9koc0pjt32ssvs9hlhcev